Oncology Brothers: Practice-Changing Cancer Discussions

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting.
 
We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including:
Common EGFR mutations and the benefits of combination therapies over single-agent osimertinib.
The role of CNS involvement in treatment decisions and the importance of patient-centered care.
Strategies for managing disease progression and the significance of re-biopsy.
Insights into ALK-positive disease, including the efficacy of lorlatinib and alectinib.
The latest developments in treating rare mutations like NTRK, MET, RET, and HER2.
With a wealth of clinical data and practical insights, this episode is packed with valuable information for oncologists and healthcare professionals. Tune in to learn how to navigate the complexities of NSCLC treatment and improve patient outcomes.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to subscribe for more discussions on oncology topics and share your thoughts in the comments below!
#LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the treatment algorithm for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations in frontline settings.
 
We discussed the latest updates in lung cancer treatment, including the recent approval of Teliso-V for C-MET overexpressing disease and Zongertinib for HER2 positive cases. We explored the nuances of choosing between single-agent and dual checkpoint inhibitors, the role of PD-L1 scores, and the impact of molecular testing on treatment decisions.
Special guest Dr. Christine Garcia, a thoracic medical oncologist and fellowship program director at Weill Cornell Medicine, shared her insights on the importance of biomarker testing, the implications of STK11 and KEAP1 mutations, and the evolving landscape of KRAS inhibitors.
Key topics covered in this episode:
The significance of NGS testing and PD-L1 scores in treatment decisions
The role of chemotherapy in high PD-L1 patients
Insights on dual checkpoint inhibitors based on recent clinical trials
The latest options for KRAS G12C mutations and C-MET overexpression
Practical considerations for managing treatment-related side effects
Tune in for an informative discussion that bridges the gap between academic research and community practice in oncology.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to subscribe for more episodes on treatment algorithms and the latest in cancer care!
#MetastaticNSCLC, #Immunotherapy, #KRASG12C, #BiomarkerTesting, #OncologyBrothers

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain dive deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with curative intent. Joined by leading thoracic medical oncologist Dr. Sanjay Popat from London, they discussed the critical role of next-generation sequencing (NGS) in treatment planning, the importance of proper staging, and the implications of actionable mutations.
 
Key topics covered included:
The significance of NGS testing and its impact on treatment decisions.
Insights from the CHECKMATE 816 trial, highlighting the benefits of neoadjuvant chemoimmunotherapy.
The complexities of post-operative immunotherapy and patient-shared decision-making.
The role of adjuvant chemotherapy in patients with actionable mutations like EGFR and ALK.
The latest data on osimertinib and alectinib in the adjuvant setting.
The standard of care for unresectable disease based on the PACIFIC trial and the implications of PD-L1 status.
Join us for an informative discussion that unpacks the latest advancements in NSCLC treatment and emphasizes the importance of personalized care.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to subscribe for more episodes in our treatment algorithm series!
#EarlyStageNSCLC, #CHECKMATE816, #NeoadjuvantTherapy, #PrecisionMedicine, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Jacob Sands, a thoracic medical oncologist from Dana-Farber Cancer Institute, to discuss the current treatment algorithms for small cell lung cancer (SCLC).
 
We dived deep into the aggressive nature of SCLC and the meaningful advances in treatment over the past few years. Key topics included:
The role of surgery and adjuvant chemotherapy in early-stage SCLC.
Insights into the ADRIATIC study, which highlighted the efficacy of Durvalumab in limited-stage disease.
The debate surrounding prophylactic cranial irradiation (PCI) and its implications for patient care.
The latest findings from the IMforte study, showcasing the combination of Atezolizumab and Lurbinectedin as a new standard of care in extensive-stage SCLC.
The promising results of Tarlatamab in the second-line setting and its impact on overall survival.
 
Join us as we explored these advancements and their potential to improve patient outcomes in the fight against small cell lung cancer.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and check out our other episodes for more insights into oncology!
#SmallCellLungCancer, #SCLC, #ADRIATIC, , #IMforte, #OncologyBrothers

Welcome to the third episode of our three-part series on colorectal cancer! In this episode of the Oncology Brothers we are joined by Dr. Rona Yaeger, a medical oncologist from the Memorial Sloan Kettering Cancer Center. Together, we dived into the management of common side effects associated with systemic treatments for colorectal cancer.
 
Episode Highlights:• Overview of 5-FU and capecitabine, including the importance of DPYD mutation testing and side effects like cytopenia, mucositis, and cardiac toxicity.• Discussion on the use of 5-FU bolus in both metastatic and adjuvant settings.• Insights into managing oxaliplatin-induced neuropathy and the potential benefits of oral cryotherapy.• Clinical pearls for irinotecan, including the management of diarrhea and cholinergic effects.• Considerations for using Bevacizumab, including risks of hypertension, proteinuria, and blood clots.• Tips for managing side effects of anti-EGFR agents like Cetuximab and Panitumumab, including rash and infusion reactions.• An overview of oral agents such as encorafenib, TAS-102, and Regorafenib, with a focus on dosing strategies and side effect management.
 
Join us as we explore these critical topics and provide valuable insights for healthcare professionals managing colorectal cancer treatments.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to subscribe for more episodes!
#ColorectalCancer, #SideEffectManagement, #DPYDtesting, #ChemotherapyToxicity, #SupportiveCare

Welcome back to the Oncology Brothers podcast! In this second episode of our three-part series on colorectal cancer, we dived deep into the BRAF V600E mutation and its implications for metastatic colorectal cancer treatment.
 
Join us as we discussed:
The prevalence and outcomes associated with BRAF V600E mutations
Recent advances in treatment options, including the BREAKWATER study
The significance of biomarker testing and how it influences treatment decisions
The new standard of care combining Encorafenib and Cetuximab with chemotherapy
Management of overlapping side effects from targeted therapies
Strategies for sequencing treatments in patients with MSI-high disease
This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in colorectal cancer treatment. Don't miss out on the critical insights shared by our expert guest!
Be sure to check out Part 1 of our series for an overview of the colorectal cancer treatment landscape, and stay tuned for Part 3, where we will focus on toxicity management and practical clinical pearls.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Subscribe to our channel for more oncology insights and updates!
This discussion was in support of an independent educational grant provided by Pfizer

In this episode of the Oncology Brothers podcast, we kicked off a three-part series on colorectal cancer, starting with the current treatment algorithm. They are joined by Dr. Smitha Krishnamurthi, a GI medical oncologist from the Cleveland Clinic, who walks through the evolving standard of care from early-stage disease all the way to refractory metastatic settings.
Key topics discussed included:
The evolving role of ctDNA as both a prognostic and predictive tool in stage two and three colon cancer, including its utility in oligometastatic disease surveillance.
Neoadjuvant versus adjuvant immunotherapy in MSI-high resectable colon cancer, comparing the NICHE-2 and ATOMIC trial approaches and when to use each.
Single-agent versus dual checkpoint inhibition with Nivo-Ipi for MSI-high metastatic disease, based on CHECKMATE-8HW data showing a PFS hazard ratio of 0.21.
Sequencing strategies in RAS-mutant and RAS wild-type metastatic colorectal cancer, including the role of sidedness, anti-EGFR therapy, and refractory options like fruquintinib, TAS-102, and regorafenib.
Join us for this comprehensive discussion on colorectal cancer management in 2026.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!
#ColorectalCancer, #MSIHigh, #BRAFV600E, #ctDNA, #GIOncology, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of pancreatic cancer treatment with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center.
 
Join us as we explored:
The challenges of diagnosing and treating pancreatic cancer, particularly in metastatic settings.
The importance of germline testing and next-generation sequencing (NGS) in guiding treatment decisions.
The role of neoadjuvant and adjuvant therapies, including FOLFIRINOX and Gemcitabine-based regimens.
Strategies for managing borderline resectable disease and the significance of multidisciplinary care.
The critical aspect of supportive care, including the use of pancreatic enzyme replacement therapy.
Insights into treatment options for metastatic disease, including FOLFIRINOX, NALIRIFOX, and Gemcitabine-Nab-paclitaxel.
The emerging landscape of targeted therapies for KRAS mutations and the potential of pan-RAS inhibitors.
 
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving treatment algorithms for pancreatic cancer.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more discussions on cancer treatment and care!
#PancreaticCancer, #KRASmutation, #NeoadjuvantTherapy, #SupportiveCare, #OncBrothers

In this episode of the Oncology Brothers, we welcomed Dr. Suneel Kamath from the Cleveland Clinic to discuss the complex landscape of biliary tract cancer. While this cancer type is not the most common, it carries a poor prognosis, making it crucial for oncologists to stay informed about the latest treatment options.
 
Join us as we explored:
The role of surgery and adjuvant chemotherapy in early-stage biliary tract cancer.
Frontline treatment strategies for metastatic disease, including insights from the TOPAZ-1 and KEYNOTE-966 studies.
The importance of biomarker testing, including HER2, IDH1, and FGFR mutations, and how they influence treatment decisions.
Management of side effects associated with various therapies, including immunotherapy and chemotherapy.
The emerging landscape of targeted therapies and the need for more effective treatment options.
Whether you're a medical professional or someone interested in oncology, this episode provides valuable insights into the current treatment algorithms and challenges in managing biliary tract cancer.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#BiliaryTractCancer, #Cholangiocarcinoma, #Immunotherapy, #BiomarkerTesting, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of Cancer of Unknown Primary (CUP). Joined by Dr. Harry Fuentes Bayne and Dr. Thor Halfdanarson from the Mayo Clinic, they discussed the current standard of care, diagnostic workup, and treatment options for this challenging condition.
 
Key topics included:
Initial diagnostic approaches for CUP, including imaging and tissue sampling
The role of immunohistochemistry (IHC) and tumor markers in guiding treatment
The use of next-generation sequencing (NGS) and tools like Cancer Type ID
Treatment strategies, including chemotherapy regimens and the potential for immunotherapy
The importance of thorough workup and palliative care in managing CUP
Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the latest approaches for diagnosing and treating cancer of unknown primary origin.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and FDA approvals. Join us on this journey through the world of oncology!
#CancerOfUnknownPrimary, #CUP, #NGS, #Immunohistochemistry, #OncologyBrothers